CAICaris Life Sciences, Inc.
Is the price fair?
A demanding price: priced for a lot of growth and rich vs its sector.
Priced for ~39% a year FCF growth. The price already bakes in strong, sustained growth.
Sector median 22.6× across 130 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.
All from derived, as of Jun 30, 2026.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What CAI's price assumes
Caris Life Sciences, Inc. has no trailing P/E on file, so the price is measured against sales instead: 5.34× revenue.
Price / sales · no trailing P/E on file: measured against sales instead
- Free cash flow yield
- 0.45%
Free cash flow yield · Biotechnology median 3.6%
- Growth the price implies
- +39%
Growth the price implies · What free cash flow would have to do every year for a decade to justify today's price, discounted at 9.0%.
- Price / book
- 8.93
Price / book · today's price, trailing year to Jun 30, 2026
Details›
- Price / booktoday's price, trailing year to Jun 30, 2026
- 8.93
- EV / EBITtoday's price, trailing year to Jun 30, 2026
- 36.4
- EV / salestoday's price, trailing year to Jun 30, 2026
- 5.64
- Free cash flow, trailing twelve months
- $24M
- Market capitalisation
- $5.29B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Biotechnology
The closest names by size in the same industry